Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Overview - Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing drug candidates that target muscle biology for treating diseases with compromised cardiac muscle performance [3] - The company is developing several drug candidates, including aficamten, a cardiac myosin inhibitor, and omecamtiv mecarbil, a cardiac myosin activator, aimed at treating various forms of heart failure [3] Upcoming Events - Robert I. Blum, President and CEO of Cytokinetics, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:00 AM Pacific Time [1] - Interested parties can access the live webcast of the presentation on the Cytokinetics website, with a replay available for 90 days post-event [2] Product Development - Aficamten is being prepared for potential commercialization following positive results from the SEQUOIA-HCM Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy [3] - The company is also evaluating aficamten in additional clinical trials for both obstructive and non-obstructive hypertrophic cardiomyopathy [3] - Other drug candidates include CK-586, targeting heart failure with preserved ejection fraction, and CK-089, aimed at specific muscular dystrophies and impaired skeletal muscle function [3]